查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798889

Gadoquatrane的全球市场

Gadoquatrane
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 273 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球Gadoquatrane市场规模将达到 24 亿美元

全球Gadoquatrane市场规模预计在2024年为19亿美元，预计到2030年将达到24亿美元，2024年至2030年的复合年增长率为3.4%。本报告分析的细分市场之一—筛检应用—预计复合年增长率为2.7%，到分析期结束时规模将达到14亿美元。诊断应用细分市场在分析期间内的复合年增长率预计为4.6%。

美国市场规模估计为 5.278 亿美元，中国市场预计复合年增长率为 6.2%

预计到2024年，美国的Gadoquatrane市场规模将达到5.278亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到4.662亿美元，在2024-2030年的分析期间内，复合年增长率为6.2%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.4%和2.6%。在欧洲，预计德国市场的复合年增长率为1.9%。

全球Gadoquatrane市场—主要趋势与驱动因素摘要

Gadoquatrane为何在诊断影像领域引起关注？

Gadoquatrane是新一代大环钆基显影剂(GBCA)，用于磁振造影(MRI)。其研发旨在提升成像性能的同时增强安全性，尤其适用于需要反覆扫描的患者。 Gadoquatran 的分子结构与Gadoquatrane离子紧密结合，最大限度地降低了钆离子解离的风险，并降低了钆在组织中滞留的可能性。鑑于上一代显影剂存在钆长期蓄积的隐患，这项改进至关重要。

在临床实务中，Gadoquatrane可用于更清晰地显示血管、器官、肿瘤和病变等病理结构。其强大的鬆弛特性支持低剂量高解析度成像，尤其适用于儿童和肾功能受损患者。随着神经内科、肿瘤科和心血管诊断领域对高精度、高对比MRI的需求不断增长，Gadoquatrane作为更安全、诊断清晰度更高的替代方案，正日益受到关注。该产品正被寻求平衡影像品质和病患安全的放射科所采用。

配方进步和安全性如何支持采用？

像钆夸Gadoquatrane）这样的大环显影剂以其化学稳定性和较低的游离钆离子释放倾向而闻名。Gadoquatrane在此基础上，提高了动力学惰性，并降低了肾源性系统性纤维化 (NSF) 的风险。 NSF 是一种罕见但严重的钆相关疾病，常见于肾功能受损患者。这些特性已在註册申报资料和临床方案中得到强调，使Gadoquatrane适用于更广泛的患者群体。

该药剂在临床场强下具有高弛豫率，可缩短扫描时间并提高影像对比度，从而实现更有效率的成像工作流程，并提高软组织异常检测的诊断准确性。该药剂与标准核磁共振造影系统和显影剂输送系统相容，可无缝整合到现有影像设备中，使医疗保健提供者无需进行大规模基础设施升级即可轻鬆过渡。

哪些临床和监管趋势正在塑造市场潜力？

由于神经系统疾病、癌症筛检和心血管疾病评估的增多，全球 MRI 扫描量持续成长。这一趋势促使医疗保健提供者寻求能够提供卓越影像品质同时最大程度降低安全隐患的显影剂。监管机构也越来越重视显影剂的安全性，鼓励使用钆释放风险较低的显影剂。Gadoquatrane)满足了这些偏好，使其成为医院和诊断影像中心的首选。

大环类药物越来越多地被纳入临床指南和采购框架，这促进了其在医疗机构中的应用。有利于先进诊断程序的报销政策也推动了其广泛应用，尤其是在新兴市场。随着临床医生和患者对钆滞留的认识不断提高，对更安全显影剂的需求预计将持续增长。正在进行的临床研究正在扩大Gadoquatrane在特殊诊断影像应用中的使用，例如中枢神经系统病变的检测和儿科放射学。

Gadoquatrane市场的成长受到多种因素的推动...

Gadoquatrane市场的成长受到多种因素的推动，包括对更安全的钆基 MRI显影剂的需求不断增长、诊断成像量的不断扩大以及药物配方的技术改进。人们对钆组织滞留的日益担忧正推动人们转向动力学稳定性更高的大环化合物。Gadoquatrane以低剂量提供高弛豫率的能力有助于改善神经病学、肿瘤学和血管诊断中的影像结果。对低风险显影剂的监管支持以及与不断发展的安全标准的一致性将推动医院和门诊市场的扩张。随着医疗保健提供者寻求高效、高解析度且安全性经过验证的影像工具，Gadoquatrane作为下一代先进 MRI 诊断的选择正日益受到关注。

部分

应用程式（筛检应用程式、诊断应用程式）；最终用户（医院最终用户、诊断中心最终用户、专科诊所最终用户、其他最终用户）

受访公司范例

  • Bayer AG
  • Bracco Imaging SpA
  • Canon Medical Systems
  • Curium Pharma
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Glenmark Pharmaceuticals
  • Guerbet Group
  • Hitachi Medical Systems
  • Lantheus Medical Imaging
  • Mallinckrodt Pharmaceuticals
  • Nihon Medi-Physics
  • Philips Healthcare
  • Siemens Healthineers
  • Sinerga SpA
  • Shenzhen YHLO Biotech
  • Simcere Pharmaceutical Group
  • Shenzhen Wanliyang Medical
  • Troikaa Pharmaceuticals
  • Unistar Medical

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP38862

Global Gadoquatrane Market to Reach US$2.4 Billion by 2030

The global market for Gadoquatrane estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Screening Application, one of the segments analyzed in the report, is expected to record a 2.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Diagnosis Application segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$527.8 Million While China is Forecast to Grow at 6.2% CAGR

The Gadoquatrane market in the U.S. is estimated at US$527.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$466.2 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Gadoquatrane Market - Key Trends & Drivers Summarized

Why Is Gadoquatrane Gaining Attention in Diagnostic Imaging?

Gadoquatrane is a next-generation macrocyclic gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI). It has been developed to offer improved imaging performance with enhanced safety features, particularly for patients requiring repeated scans. Gadoquatrane’s molecular structure provides strong binding of gadolinium ions, minimizing the risk of dissociation and reducing the likelihood of gadolinium retention in tissues. This has become an important consideration following concerns over long-term gadolinium accumulation associated with earlier-generation contrast agents.

In clinical practice, gadoquatrane is used to enhance visualization of blood vessels, organs, and pathological structures such as tumors and lesions. Its strong relaxivity properties support high-resolution imaging at lower doses, which is especially valuable in pediatric and renal-impaired patients. As demand for accurate, high-contrast MRI continues to rise in neurology, oncology, and cardiovascular diagnostics, gadoquatrane is increasingly viewed as a safer alternative with superior diagnostic clarity. The product is being adopted by radiology departments aiming to balance image quality with patient safety.

How Are Formulation Advances and Safety Profiles Supporting Adoption?

Macrocyclic contrast agents like gadoquatrane are known for their chemical stability and low propensity to release free gadolinium ions. Gadoquatrane builds on this foundation by offering enhanced kinetic inertness and reduced risk of nephrogenic systemic fibrosis (NSF), a rare but serious condition linked to gadolinium in patients with impaired kidney function. These characteristics are being emphasized in regulatory filings and clinical protocols, making gadoquatrane suitable for broader patient groups.

Another factor aiding adoption is the agent’s high relaxivity at clinical field strengths, which allows for shorter scan times and sharper image contrasts. This enables more efficient imaging workflows and greater diagnostic precision in detecting soft tissue abnormalities. Compatibility with standard MRI equipment and contrast delivery systems allows seamless integration into existing imaging setups, making it easier for healthcare providers to transition without significant infrastructure upgrades.

What Clinical and Regulatory Trends Are Shaping Market Potential?

MRI scan volumes continue to increase globally, driven by rising incidence of neurological disorders, cancer screening, and cardiovascular disease evaluation. These trends are leading healthcare providers to seek contrast agents that offer superior image quality with minimal safety concerns. Regulatory bodies are increasingly focusing on contrast agent safety, encouraging the use of agents with lower gadolinium release risk. Gadoquatrane aligns well with such preferences, positioning it as a preferred option for hospitals and diagnostic imaging centers.

Institutional adoption is supported by growing inclusion of macrocyclic agents in clinical guidelines and purchasing frameworks. Reimbursement policies that favor advanced diagnostic procedures also support wider uptake, particularly in developed markets. As awareness around gadolinium retention grows among clinicians and patients, demand for safer contrast solutions is expected to continue rising. Ongoing clinical studies are expanding the scope of gadoquatrane in specialized imaging applications, such as CNS lesion detection and pediatric radiology.

Growth in the Gadoquatrane Market Is Driven by Several Factors…

Growth in the gadoquatrane market is driven by several factors including increasing demand for safer gadolinium-based MRI contrast agents, expanding diagnostic imaging volumes, and technological improvements in agent formulation. Rising concern over tissue retention of gadolinium is prompting a shift toward macrocyclic compounds with higher kinetic stability. Gadoquatrane’s ability to deliver high relaxivity at low doses supports improved imaging outcomes in neurology, oncology, and vascular diagnostics. Regulatory support for low-risk contrast agents and alignment with evolving safety standards facilitate market expansion across hospital and outpatient settings. As healthcare providers seek efficient, high-resolution imaging tools with proven safety profiles, gadoquatrane is gaining traction as a next-generation option in advanced MRI diagnostics.

SCOPE OF STUDY:

The report analyzes the Gadoquatrane market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Screening Application, Diagnosis Application); End-User (Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Bayer AG
  • Bracco Imaging S.p.A.
  • Canon Medical Systems
  • Curium Pharma
  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Glenmark Pharmaceuticals
  • Guerbet Group
  • Hitachi Medical Systems
  • Lantheus Medical Imaging
  • Mallinckrodt Pharmaceuticals
  • Nihon Medi-Physics
  • Philips Healthcare
  • Siemens Healthineers
  • Sinerga S.p.A.
  • Shenzhen YHLO Biotech
  • Simcere Pharmaceutical Group
  • Shenzhen Wanliyang Medical
  • Troikaa Pharmaceuticals
  • Unistar Medical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Gadoquatrane - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safer and More Stable MRI Contrast Agents Drives Clinical Interest in Gadoquatrane Formulations
    • Increased Concerns Over Gadolinium Retention in Patients With Renal Impairment Spur Development of Macrocyclic Agents Like Gadoquatrane
    • Growth in MRI Procedures Across Oncology, Neurology, and Cardiovascular Imaging Supports Adoption of Novel Contrast Agents
    • Advancements in Contrast Agent Design Enhance Stability, Relaxivity, and Diagnostic Accuracy in Gadoquatrane-Based Products
    • Surge in Gadolinium-Free and Low-Dose Alternatives Positions Gadoquatrane as a Viable Macrocyclic Solution With Enhanced Safety Margins
    • Expansion of Pediatric and Geriatric Imaging Services Highlights Demand for Well-Tolerated, Low-Toxicity Contrast Media
    • Improved Shelf-Life, Storage Stability, and Compatibility With MRI Modalities Support Hospital Adoption of Gadoquatrane
    • Increasing Investment in Radiopharmaceutical R&D Creates Opportunities for Dual-Function Imaging and Contrast Agents
    • Use in High-Resolution Brain and Vascular Imaging Scenarios Expands Clinical Applications for Gadoquatrane-Based Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Gadoquatrane Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Gadoquatrane by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Screening Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Screening Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Diagnosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gadoquatrane by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Gadoquatrane by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Gadoquatrane by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Gadoquatrane by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Gadoquatrane by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Gadoquatrane Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Gadoquatrane by Application - Screening Application and Diagnosis Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Gadoquatrane by Application - Screening Application and Diagnosis Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Gadoquatrane by Application - Percentage Breakdown of Value Sales for Screening Application and Diagnosis Application for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Gadoquatrane by End-user - Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Gadoquatrane by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Diagnostic Centers End-User, Specialty Clinics End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION